[Pathophysiology and new treatment for hereditary neuropathy].
Nodera
Hiroyuki
H
Department of Clinical Neuroscience, Graduate School of Medicine, the University of Tokushima, 2-50-1 Kuramotocho, Tokushima city, Tokushima 770-8503, Japan.
Kaji
Ryuji
R
D000818:Animals; D001205:Ascorbic Acid / Q000627:therapeutic use; D002607:Charcot-Marie-Tooth Disease / Q000235:genetics* / Q000503:physiopathology* / Q000628:therapy; D017630:Connexins / Q000235:genetics; D004594:Electrophysiology; D006067:Gonanes / Q000627:therapeutic use; D006727:Hormone Antagonists / Q000627:therapeutic use; D006801:Humans; D051379:Mice; D018993:Myelin P0 Protein / Q000235:genetics; D009185:Myelin Proteins / Q000235:genetics*; D017933:Peripheral Nervous System / Q000503:physiopathology; D015221:Potassium Channels / Q000502:physiology; D011506:Proteins / Q000235:genetics; D051381:Rats; D000097002:Gap Junction beta-1 Protein
D001205:Ascorbic Acid; D017630:Connexins; D006067:Gonanes; D006727:Hormone Antagonists; D018993:Myelin P0 Protein; D009185:Myelin Proteins; D015221:Potassium Channels; D011506:Proteins; D000097002:Gap Junction beta-1 Protein; C109561:CDRT1 protein, human; C073687:PMP22 protein, human; C053238:onapristone